Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $174.0M | $66.2M | $63.4M | $125.0M | $238.5M | $379.3M | $459.1M | $445.8M | $1,378.5M | $2,104.7M | $2,819.6M | $4,103.7M | $4,860.4M | $5,872.2M | $6,710.8M | $7,863.4M | $8,497.1M | $16.1B | $12.2B | $13.1B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Regeneron Pharmaceuticals, Inc.'s last 12-month Revenue is $13.8B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Regeneron Pharmaceuticals, Inc.'s Revenue growth was 5.7%. The average annual Revenue growth rates for Regeneron Pharmaceuticals, Inc. have been 14.6% over the past three years, 12.7% over the past five years.
Over the last year, Regeneron Pharmaceuticals, Inc.'s Revenue growth was 5.7%, which is higher than industry growth of 3.1%. It indicates that Regeneron Pharmaceuticals, Inc.'s Revenue growth is Good.